bpc-157 safety human trials FDA advisory committee votes to add popular peptide to drug compounding list bpc-157 human clinical trials evidence

You may see modest weight reduction after 4-8 weeks when combined with proper diet and exercise

What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy

Risk-benefit analysis should consider the severity and impact of the condition being treated, failure or limitations of conventional therapies, individual patient risk factors particularly for malignancy, and patient preferences regarding experimental treatments

The 2-4% range represents the optimal balance between effectiveness and tolerability for most users